L1 cell adhesion molecule (L1-CAM) is a transmembrane cell adhesion molecule involved in cell migration and axon guidance in the developing nervous system. L1 is also overexpressed in ovarian and endometrial carcinomas and is associated with a bad prognosis. In carcinoma cell lines, L1 overexpression augments cell motility, tumor growth in mice and induces expression of Erk-dependent genes. Here, we show that a mutation in the cytoplasmic portion of L1 (T1247A, S1248A) abrogates Erk activation, blocks cell migration on extracellular matrix proteins and did not augment tumor growth in non-obese diabetic/severe combined immuno-deficient mice. In cells expressing mutant L1, the induction of Erk-dependent genes such as b3-integrin, cathepsin-B and several transcription factors is eliminated and the invasive phenotype is abrogated. L1 antibodies showed similar effects. They prevented Erk activation and interfered with the Erk-dependent gene expression pattern. These findings provide a rationale for the mode of action of L1 antibodies and suggest that interference with L1 function could become a valuable target for therapy.
Introduction
L1 cell adhesion molecule (L1-CAM) is a 200-220 kDa transmembrane glycoprotein of the immunoglobulin (Ig) superfamily initially identified in neural cells. It is composed of six Ig-like domains and five fibronectin type III repeats followed by a transmembrane region and a highly conserved cytoplasmic tail (Moos et al., 1988) . Recent studies have shown that the L1 molecule plays an important role in the ontogeny of human tumors (Senner et al., 2002; Thies et al., 2002; Fogel et al., 2003a, b; Allory et al., 2005; Gavert et al., 2005; Shtutman et al., 2006) . In melanoma and ovarian/ endometrial carcinoma, L1 expression is associated with poor prognosis (Thies et al., 2002; Fogel et al., 2003a, b) . The mechanism by which L1 contributes to tumor progression has not been clearly established.
Previous studies have demonstrated that the ectopic expression of L1 augments tumor growth in non-obese diabetic/severe combined immuno-deficient (NOD/ SCID) mice, enhances cell motility on extracellular matrix proteins and increases matrigel invasion (Mechtersheimer et al., 2001; Thelen et al., 2002; Silletti et al., 2004; Gast et al., 2005; Gavert et al., 2005; Meier et al., 2006) . Interference with L1 expression by genetic manipulation was found to be growth inhibitory in vitro (Primiano et al., 2003) . Importantly, a recent study has demonstrated that L1 can induce extracellular signal-regulated kinase (Erk)-dependent gene regulation (Silletti et al., 2004) . Meanwhile, antibodies to L1 were shown to have therapeutic potential and can reduce cell proliferation in vitro and in vivo growth of SKOV3ip human ovarian carcinoma cells in a xenograft mouse model (Primiano et al., 2003; Arlt et al., 2006; Knogler et al., 2007) . Thus, a better understanding of L1 signaling in carcinoma cells and the mode of action of L1 antibodies is needed.
In this report, we have analysed closer the functional role of L1 in human carcinoma cells. We confirm that L1 expression indeed led to altered gene expression, enhanced motility, invasiveness in vitro and tumor growth in NOD/SCID mice. The activation of the MAPK Erk seems to be critical for L1-mediated gene regulation. We identified two amino acids in the intracellular domain of L1 (T1247A, S1248A; human L1 with mutations of T1247A and S1248A (hL1mutTS)) that are involved in Erk activation. Concomitantly, hL1mutTS-expressing cells lost the ability to regulate Erk-dependent gene transcription and to augment tumor growth. Strikingly, L1 antibodies showed similar effects. They prevented Erk activation and interfered with the Erk-dependent gene expression pattern. These findings provide a rationale for the mode of action of L1 antibodies and suggest that interference with L1 function could become a valuable target for therapy.
Results
The cytoplasmic part is important for L1-enhanced cell motility and matrigel invasion We initially compared HEK293 cells stably transduced with human L1 (hL1) or a deletion mutant missing the cytoplasmic portion of L1 (hL1-1147) (Cheng et al., 2005a) . We noted that the previously observed L1-augmented invasion and cell motility were lost in the deletion mutant (Figures 1c and d ; compare HEK293-hL1 versus hL1-1147) suggesting that the cytoplasmic portion of L1 was required for these effects.
We searched for amino acids within the cytoplasmic portion of L1 responsible for the functional suppression. The cytoplasmic part contains a putative Src homology 3 binding domain with the consensus sequence PINP (Position 1249-1252). The proceeding amino acid Serine1248 was previously identified as a phosphorylation site for Erk2 (Schaefer et al., 1999) . Given the known role of Erk in L1-mediated gene regulation (Silletti et al., 2004) and L1-promoted cell motility (Thelen et al., 2002) , we altered the Erk phosphorylation site (S1248A) by site-directed alanine mutagenesis (human L1 with a mutation of S1248A, hL1mutS). A second mutant was constructed including the adjacent threonine (T1247A, S1248A) and was termed hL1mutTS (see Figure 1a ). Both mutants were stably expressed in HEK293 cells. Fluorescence-activated cell sorting (FACS) analysis revealed the expression at the cell surface ( Figure 1b) .
Cells expressing hL1mutS showed enhanced motility similar to hL1 (Figure 1c ). In contrast, cells expressing hL1mutTS had lost this ability (Figure 1c) . Similar results were observed in matrigel invasion assays (Figure 1d ). To exclude changes in integrin expression as the mechanism behind motility effects, the adhesion to fibronectin and laminin was examined. No significant differences in the adhesion to fibronectin or laminin between HEK293 cells expressing hL1 or hL1mutTS was detected (data not shown). Thus, by mutagenesis of two amino acids in the cytoplasmic part of L1, we were able to mimic the effect of the hL1-1147 deletion mutant. We concentrated on the characterization of hL1mutTS.
hL1mutTS-expressing cells show a reduced tumor growth compared to hL1 cells L1 augments the tumor growth in xenotransplanted mice Gavert et al., 2005) . We therefore examined the effects of hL1mutTS on tumor growth in NOD/SCID mice. As expected, we observed enhanced growth of HEK293-hL1 tumors in comparison to untransfected HEK293 tumors (Figures 2a  and b) . Strikingly, HEK293-hL1mutTS cells did not show augmented tumor growth in NOD/SCID mice (Figures 2a and b) .
We verified these results in a second model system composed of SW707 colon carcinoma cells. SW707-hL1 cells revealed augmented tumor growth in vivo in agreement with previous results (Gavert et al., 2005) . Cells expressing hL1mutTS showed similar in vivo growth as mock-transfected SW707 cells (Figure 2c ). These results suggested that the TS1247/1248AA mutation had eliminated the growth-promoting ability of L1. Earlier studies had demonstrated that L1 can effect the expression of Erk-dependent genes (Silletti et al., 2004) . We asked whether this applied also to our HEK293 and HEK293-hL1 cells and investigated gene expression by chip analysis. Differential hybridization revealed that of the 1920 cDNAs on the chip, appr. 448 were up-or downregulated more than onefold in HEK293-hL1 cells ( Figure 3a) . We concentrated our analysis on genes important for invasion, motility and tumor growth regulation. Several identified genes were examined by qRT-PCR at the mRNA level. In HEK293-hL1 cells, we observed upregulation of genes such as cathepsin-B, b3-integrin and the transcription factors HOXA9 and AP2a, respectively. The apoptosis-related gene Mdm2 was also upregulated whereas downregulation was noticed for the retinoic acid (RA)-binding protein cellular retinoic acid-binding protein II (CRABPII) and the apoptosis-inducing genes STK39 and IER3 ( Figure 3b ). Strikingly, the same set of genes remained unchanged in hL1mutTS-expressing cells and was similar to nontransfected cells ( Figure 3b ). Similar observations were made in the colon carcinoma cell line SW707 (data not shown).
At the protein level the results were verified by western blot analysis for cathepsin-B and CRABPII ( Figure 3c ) and for b3-integrin by FACS analysis (Figure 3d ). These results confirmed and extended previous data (Silletti et al., 2004) by showing that L1 expression affects gene expression levels. Strikingly, this ability was lost in hL1mutTS.
hL1mutTS is deficient in Erk activation
Previously, L1 was shown to cause sustained Erk activation, leading to enhanced activity of Erk-dependent genes (Silletti et al., 2004) . We asked whether hL1mutTS had lost the ability to induce Erk activation. We observed in HEK293-hL1 cells a constitutive Erk phosphorylation ( Figure 4a ) in agreement with previous studies (Silletti et al., 2004; Gavert et al., 2005) . In contrast, in hL1mutTS-expressing cells decreased phosphorylation of Erk was seen ( Figure 4a ).
To examine a possible role of Src in Erk activation, we analysed the phosphorylation status of Src. We observed enhanced activation of Src in HEK293-hL1 cells compared to HEK293-hL1mutTS cells (Figure 4a ). To investigate a role of Src in L1-dependent Erk activation, we carried out Src knockdown experiments. Src-specific siRNAs suppressed Erk phosphorylation in HEK293-hL1 cells (Figure 4b ). A similar suppression was noted in cells treated with the Src-specific inhibitor PP2 (data not shown). We concluded that L1-dependent phosphorylation of Erk involved Src in HEK293-hL1 cells. This pathway was most likely defective in cells expressing hL1mutTS.
RanBPM can be co-precipitated with L1 and was shown to link L1 to the Erk pathway (Cheng et al., 2005b) . Indeed, analysis by western blot showed that RanBPM was expressed in various carcinoma cell lines (Figure 4c ). We examined whether the association with RanBPM was impaired in HEK293-hL1mutTS cells. We observed no difference in the amount of RanBPM co-precipitated from HEK293-hL1 versus HEK293-hL1mutTS cells (Figure 4d ). These results suggested that a lack of RanBPM association was not the reason for the suppressed Erk activation in hL1mutTS cells.
Antibodies to L1 alter L1-dependent signaling in ovarian carcinoma cells We have previously shown that antibodies to L1 can suppress the tumor growth of SKOV3ip cells in a L1 signaling and antibody therapy D Gast et al xenograft mouse model (Arlt et al., 2006; Knogler et al., 2007) . Therefore, we examined in more detail the effects of mAb on L1-mediated signaling. We observed that the incubation of SKOV3ip cells with mAb L1-11A caused a time-dependent loss of Src and Erk activation (Figure 5a ). Similar results were noted in the ovarian carcinoma cell line OVMz (data not shown).
To analyse whether the effects of the L1-mAb were transient or long lasting, we incubated SKOV3ip cells for 24 h. In addition to mAb L1-11A, we included the novel mAbs L1-9.3, L1-14.10 and L1-38.12. The mAbs L1-11A, L1-14.10 and L1-9.3 efficiently blocked Erk phosphorylation in vitro (Figure 5b ). There was no inhibition with isotype-matched control antibody or the mAb L1-38.12 that binds only the neural isoform but not the tumor isoform of L1 (PA, unpublished data). Fluorescent analysis with the phospho-specific Erk antibody confirmed a clear reduction of activated Erk in L1-mAb-treated cells (Figure 5c ).
L1-mAb affects gene expression
We next examined whether L1-mAb affected the gene expression profile of SKOV3ip cells. Therefore, cells were treated for 96 h with L1-mAb and analysed by qRT-PCR analysis. Indeed, cells treated with L1-11A versus control antibody showed significant changes in the expression of L1-regulated genes (Figure 6a ). Whereas the L1-mAb treatment reduced the expression of HOXA9, and b3-integrin, the expression of CRAB-PII, IER3 and STK39 were enhanced (Figure 6a) . Thus, the L1-mAb treatment reverted the effects of L1-mediated overexpressing cells (see Figure 3b) .
We argued that the depletion of L1 by siRNA might induce similar effects than the treatment with L1-mAb. To analyse this question, we transiently depleted L1 by siRNA and examined Erk activation and the expression of our predefined gene set. As shown in Figure 6b , the L1 knockdown completely abrogated L1 expression. At the same time, the levels of phosphorylated Src and Erk were reduced. Strikingly, the siRNA-mediated L1 knockdown caused similar changes in the expression levels of genes as the treatment with L1-mAb (Figure 6c ).
L1-mAbs affect tumor growth and gene expression in vivo
Having established that L1-mAbs could interfere with Erk phosphorylation, we analysed the capacity of novel L1-mAbs in functional assays. All mAbs to L1 blocked (Figure 7a ). We also observed a partial inhibition of the growth of SKOV3ip cells in nude mice (Figure 7b ) reconfirming our previous data (Arlt et al., 2006) . The EpCAM-specific mAb HEA125 had no effect on tumor growth (Figure 7b ).
In an independent experiment, we tested whether L1-mAb had influenced the gene expression of SKVO3ip cell in vivo in a similar fashion as in vitro. To this end, mRNA from the residual tumor of mAb L1-9.3-treated mice or control mice were isolated and subjected to qRT-PCR analysis. L1-mAb treatment led to significant downregulation of L1-dependent genes as demonstrated for HOXA9, b3-integrin and IER3 (Figure 7c ).
Discussion
L1 is a type 1 transmembrane protein that is overexpressed in many human carcinomas and melanomas and has been linked to poor prognosis. Here, we demonstrate that (1) the expression of hL1 augments cell motility, invasiveness and tumor growth; (2) the presence of hL1 causes sustained Erk activation and augments transcriptional activity of proinvasive genes; (3) the mutation T1247A/S1248A in the cytoplasmic portion abolishes all L1-mediated effects and (4) antibodies to L1 had similar effects as hL1mutTS by suppressing Erk activation, and reverting the transcriptional program. These results strongly suggest that Erk activation is required for L1-dependent signaling that can be targeted with L1 antibodies.
We observed that the expression of L1 lead to global changes in gene expression profiles in HEK293 and SW707 carcinoma cells. In more detail, we observed that transcription factors such as AP2a and HOXA9 were upregulated in hL1-expressing cells. Based on their role in gene regulation, these transcription factors could perform a relevant role in tumor progression (Bar-Eli, 2001 ). In agreement with Silletti et al. (2004) , we could show that proinvasive proteins such as the cysteine protease cathepsin-B and the motility associated b3-integrin were upregulated in L1-expressing cells. Furthermore, the cellular retinoic acid-binding protein CRABPII, that is known to be a tumor suppressor, was significantly downregulated in L1-expressing cells. CRAB-PII channels RA to retinoic acid receptor, thereby enhancing the transcriptional activity of the receptor. RA can suppress cell proliferation and transcription (Lotan, 1996) . Collectively, our analysis confirms and extents the observation by Silletti et al. Of great value for our study was the identification of two amino acids in the cytoplasmic part that have a pivotal role in L1 signaling. In all functional aspects (motility, invasiveness, gene regulation and tumor growth), hL1mutTS-expressing cells behaved like cells that do not express L1. This suggested that the point mutations had rendered the L1 protein functionally inactive. Importantly, the mutant protein efficiently suppressed L1-mediated Erk activation. An intriguing question is why hL1mutTS is defective in Erk activation. Earlier studies have shown that Src is required for enhanced cell motility of L1 expressing cells (Thelen et al., 2002) . The expression of a dominant-negative Src (K295M) mutant in L1-transfected HEK293 cells decreased L1-potentiated migration to the level of untransfected cells. C-Src is required for endocytosis of L1 (Schaefer et al., 1999; Schmid et al., 2000) , the regulation of neurite outgrowth on L1-coated surfaces (Ignelzi et al., 1994) , L1-induced Erk activation (Schaefer et al., 1999; Silletti et al., 2004 ) and cleavage of L1 by A disintegrin and metalloprotease 10 (Gutwein et al., 2000) . In our study, we observed higher Src activation in hL1-expressing cells and this activation was decreased in hL1mutTS cells. Erk is a downstream target of Src. Our data suggest that the loss of the T1247/S1248 motif prevented Src-dependent Erk activation. In addition, RanBPM is a novel L1-interacting protein that acts as an adapter protein linking L1 to the Erk pathway (Cheng et al., 2005b) . We failed to detect any difference in the association of wild type and mutant L1 with RanBPM. It remains to be investigated what other function of L1 is lost in hL1mutTS.
Erk1/2 are serine-threonine kinases that can phosphorylate many proteins including transcription factors, cytoskeletal proteins, membrane proteins and other kinases (Schaeffer and Weber, 1999) . Erk activation can be distinguished into either transient or sustained. The latter mode is required for the translocation of activated Erk from the cytoplasm to the nucleus where it regulates gene transcription (Schaeffer and Weber, 1999; Colucci-D'Amato et al., 2003) . Recent reports have demonstrated a close association between L1 and sustained Erk activation in carcinoma cells (Silletti et al., 2004; Gavert et al., 2005) . We observed that mAbs to L1 caused similar effects as those seen with hL1mutTS. The mAbs to L1 could drastically reduce Erk and Src activation. It is interesting to note that in neuronal cells, L1 crosslinking with antibodies led to Erk activation (Schaefer et al., 1999; Tang et al., 2006) , whereas in carcinoma cells the opposite is observed. In SKOV3ip cells that were used before as a therapy model in nude mice (Arlt et al., 2006; Knogler et al., 2007) , the treatment with L1-mAbs was accompanied by changes in the expression pattern of Erk-regulated genes. Importantly, the effects of the L1-mAbs were not only observed in vitro but were also seen in the residual tumor mass of mice after antibody treatment. This highlights the role of L1 in the regulation of Erkdependent genes and offers for the first time an explanation for the efficacy of L1-mAb in experimental therapy models.
Based on our results, we propose that loss of the TSmotif in the L1 cytoplasmic part reduces sustained activation of Erk and prevents the expression of Erkdependent genes. The same effects are observed after treatment with L1-mAbs. Although the mechanistic details have still to be elucidated, this offers the possibility to target L1 in human carcinomas. The inactivation of L1 by mAbs or overexpression of the hL1mutTS might be novel routes for blocking the growth and dissemination of tumors. 
Materials and methods

Cells and DNAs
The ovarian carcinoma cell line SKOV3ip and the colon carcinoma cell line SW707 were described before (Gutwein et al., 2003; Gavert et al., 2005) . The human epithelial kidney cell line HEK293 and SW707 cells stably expressing hL1 and mutant L1 were established by transfection with Superfect (Stratagene, Heidelberg, Germany). All cells were cultivated in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum at 37 1C, 5% CO 2 and 100% humidity. L1 mutagenesis was performed with the QuikChange Site-Directed Mutagenesis Kit essentially as described by the manufacturer (Stratagene). All constructs were verified by sequencing.
Chemicals and antibodies
Antibodies to the ectodomain of L1 (L1-11A, subclone of mAb UJ 127.11) or MAb L1-14.10 were described (Mechtersheimer et al., 2001; Huszar et al., 2006) . The mAb HEA-125 to EpCAM was previously described (Moldenhauer et al., 1987) . The novel mAbs to L1 were obtained in mice using commonly known immunization procedures. Antibodies to Erk1 or phospho-Erk were purchased from BD-Transduction (Heidelberg, Germany). Antibodies to Src and phospho-Src were purchased from Cell Signalling (Biozol Diagnostica, Eching, Germany). The antibody to b-actin was obtained from Sigma (Taufkirchen, Germany) and the antibody to RanBPM was from Epitomics (Burlingame, CA, USA). SiRNA specific for Src or L1 were obtained from MWG (MWG-Biotech AG, Ebersberg, Germany). The antibody against cathepsin-B was from Zymed (Invitrogen, Karlsruhe, Germany) and the antibody to CRABPII from Santa Cruz (Santa Cruz, Heidelberg, Germany). Secondary antibodies were obtained from Dianova (Dianova, Hamburg, Germany). The MEK inhibitor PD98059 was obtained from Calbiochem (Bad Soden, Germany).
DNA chip analysis and quantitative PCR mRNA was isolated using the Quiagen RNAeasy mini kit (Quiagen Hilden, Germany). The cDNA array contained 1920 DNA fragments of oncological relevance and 60 control genes (http://www.rzpd.de/products/microarrays/oncochip.shtml). After exposing of the hybridized membranes, the PhosphorImager screens were scanned (Fuji FLA-3000, 100 mm resolution, Fuji BAS-reader software). The primary image ) were examined in a matrigel invasion assay. (b) Tumor growth in nude mice. LacZ-tagged SKOV3ip cells were injected i.p. into nude mice and after tumor implantation animals were treated with the indicated L1-mAbs or control mAb to EpCAM (HEA-125). After 30 days the tumor volume was determined and is given as the ratio between X-Gal-stained tumor mass and the total sinus. Six animals were analysed per group. (c) SKO3ip tumor bearing animals were treated with mAb L1-9.3 leading to a substantial reduction of tumor volume. mRNAs from residual tumors or control tumors were isolated, transcribed to cDNA and analysed by qPCR for the expression of the indicated genes.
L1 signaling and antibody therapy D Gast et al analysis (estimation of nVol gray level values for each individual spot) was performed using the ArrayVision software package (Interfocus), which had been adjusted to the 5 Â 5 array before. The background was corrected locally in each 5 Â 5 field by subtracting the empty spot signal (average signal of three spots, see above). Normalization was performed via the average signal intensity (without empty spots) on the whole membrane. Two independent hybridizations were performed for each experiment. For qPCR, the cDNA was purified on Microspin G-50 columns (Amersham Biosciences, Freiburg, Germany) and quantitated by NanoDrop spectrophotometer (ND-1000, Kisker-Biotechnology, Steinfurt, Germany). Primers for qPCR were designed with the DNA Star Program and were produced by MWG-Biotech AG. b-Actin was used as an internal standard. The PCR reaction was performed with the SYBRgreen mastermix (Applied Biosystems, Darmstadt, Germany). The sequence of primers used is available on request.
Biochemical analysis
Sodium dodecyl sulfate-Polyacrylamide gel elecrophoresis and western blot analysis are described before (Gutwein et al., 2000) .
FACS analysis and immunofluorescence microscopy
The staining of cells with mAbs and PE-conjugated secondary antibodies has been described (Mechtersheimer et al., 2001) . Cells were analysed with a FACScan using Cellquest software (Becton & Dickinson, Heidelberg, Germany).
Transmigration and matrigel invasion assays
The transmigration assay has been described before (Mechtersheimer et al., 2001) . Each experiment was done in quadruplicates and the mean values7s.d. are presented. Tumor cell invasion in vitro was determined in a double-filter assay as described (Brunner et al., 1998) .
Cell adhesion assay
The cell adhesion assay has been described before (Mechtersheimer et al., 2001) .
In vivo experiments Six-week-old NOD/SCID female mice (four animals per group) were injected s.c. with 10 7 cells stably expressing hL1 or hL1mutTS. For control, untransfected HEK293 or mocktransfected SW707 cells were used. One type of cells was injected into the right flank and the other type was injected into the left flank of the same animal. Tumor growth was monitored for the indicated length of time at which point the experiment was terminated and tumors were collected for histological evaluation. At different time points the tumor was measured and the volume was calculated using the formula: V ¼ (L Â W 2 )p/6. The therapy experiments with L1-mAb and SKOV3ip cells growing in nude mice were done as described (Arlt et al., 2006) . All experiments were carried out under the German animal protection law and were approved by local authorities.
Statistical analysis
For the analysis of statistical significance the Student's t-test was used.
Abbreviations CRABPII, cellular retinoic acid-binding protein II; Erk, extracellular signal-regulated kinase; hL1, human L1; hL1mutS, human L1 with a mutation of S1248A; hL1mutTS, human L1 with mutations of T1247A and S1248A; RA, retinoic acid.
